KRAS and neoplasm: The efficacy of nanoparticles containing KRAS-targeting small interfering RNA (siRNA) has been tested in mouse models and the results suggest that targeting KRAS-mutant cells through specific siRNA might be effective for oncogene silencing and inhibition of tumor growth.